Advanced Search

 

Study ID Status Title Patient Level Data
S2WA3012 Completed A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population.
S2WA4002 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy Of Oral Naratriptan (2.5mg) For The Treatment Of Migraine In Subjects Who Do Not Respond To Oral Sumatriptan (50mg)
S2WA4003 Completed A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life.
S2WA4004 Completed A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life.
S2WA4005 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Administered Twice Daily in the Treatment of Transformed Migraine.
S2WA4006 Completed A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1mg and 2.5mg twice daily as prophylactic treatment for menstrually-associated migraine.
S2WB1002 Completed A study to compare the safety, tolerability, pharmacodynamics and pharmacokinetics of two doses of oral naratriptan (GR85548A) in young and elderly subjects.
S2WB1003 Completed A study to investigate the effect of subcutaneous sumatriptan on the safety, pharmacodynamics and pharmacokinetics of oral naratriptan.
S2WB1006 Completed A study to evaluate the ocular effects of naratriptan in healthy subjects.
S2WB2003 Completed A double-blind, placebo-controlled, randomised, parallel group study to evaluate the safety and efficacy of oral naratriptan (5mg and 10mg) following dosing during a migraine attack.
S2WB2004 Completed A double-blind, randomised, placebo-controlled, parallel group study to compare the efficacy and safety of oral naratriptan (1mg-10mg) with that of oral sumatriptan (100mg) and placebo in the acute treatment of migraine headache.
S2WB3002 Completed A randomised, double-blind, placebo-controlled, oral sumatriptan-controlled (100mg), three attack, parallel group study to determine the efficacy, safety and tolerability of oral naratriptan (0.1mg, 0.25mg, 1.0mg and 2.5mg) in the acute treatment of migraine headache.
S2WB3004 Completed An open study of the long-term safety and efficacy of oral naratriptan 2.5mg in the acute treatment of migraine.
S2WB3009 Completed A study to assess the effect of 1.5mg subcutaneous naratriptan (GR85548A) on cardiac haemodynamics in patient-volunteers with existing or suspected coronary artery disease.
S2WB3011 Completed A randomised, double-blind, two attack, cross-over study to compare the efficacy, safety and tolerability of oral naratriptan 2.5mg with oral sumatriptan 100mg in the acute treatment of migraine in patients susceptible to headache recurrence.
S2WB4001 Completed A randomised double-blind, cross-over study to investigate patient overall satisfaction with efficacy and tolerability of oral Naratriptan 2.5mg Vs oral Sumatriptan 50mg for the treatment of patients who lapse from 100mg oral or 6mg subcutaneous Sumatriptan use.
S3010567 Completed A Single Dose Bioequivalence Study of 2mg and 4mg Nicotine Lozenges
S3250493 Completed Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated with Nicotine Withdrawal
S3820642 Completed A Pharmacokinetic Evaluation of Nicotine Patches in Smokers
S3A-150 Completed An evaluation of the pharmacokinetic properties of intravenous ondansetron in children receiving chemotherapy.
S3A-154 Completed An Open Label, Randomized Evaluation of the Pharmacokinetic Properties of Intraveneous and Oral Doses of GR 38032F in Healthy, Elderly Volunteers
S3A-155 Completed An evaluation of the effect of chemotherapy on the pharmacokinetics of oral ondansetron (GR38032F).
S3A-156 Completed An evaluation of the effects of food and antacid on the absorption of oral ondansetron (GR 38032F).
S3A-157 Completed An evaluation of the steady-state pharmacokinetics of ondansetron after 1, 4 and 8 mg oral doses
S3A-158 Completed Comparison of the pharmacokinetics of ondansetron (GR38032F) in patients with various degrees of hepatic insufficiency and in normal healthy subjects.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.